Compare JMM & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMM | CTSO |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | JMM | CTSO |
|---|---|---|
| Price | $6.13 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 16.1K | ★ 126.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $5.29 | $0.60 |
| 52 Week High | $6.10 | $1.61 |
| Indicator | JMM | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 46.64 |
| Support Level | $6.06 | $0.70 |
| Resistance Level | $6.15 | $0.85 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 35.71 | 52.04 |
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.